On September 3, 2026, during a massive Russian air attack, the warehouse of the pharmaceutical company Teva in Ukraine was hit twice. All employees survived, and there were no casualties among them. The company is assessing the damage and trying to prevent disruptions in the supply of medicines.
And here is a crucial detail for Israel: it is specifically about the Ukrainian division of Israeli Teva Pharmaceutical Industries, not a local company that simply uses the well-known Israeli brand.
Author: Victoria Katsman
For NANews — News of Israel, this story is also important because Teva has been operating in Ukraine for almost three decades, is among the top three leaders in the local pharmaceutical market, and after the start of the full-scale war, it provided the country with humanitarian aid worth more than $155 million. Now the company’s own infrastructure has come under Russian attack.
Massive attack on September 3: Teva was just one of the affected sites
On the night of September 3, Russia launched 163 drones at Ukraine. Among them were Shahed, including jet versions, S8000 “Parcel”, “Gerbera”, and decoy drones.
The Ukrainian Air Force reported 135 drones shot down or suppressed. Hits were recorded in 15 locations, and debris from downed targets fell in four other places.
Against this backdrop, two strikes on the Teva warehouse occurred.
It is important not to repeat the mistake of the initial reports and not to call the incident a “double missile strike.” Teva itself officially confirms two strikes but does not specify that they were missiles. Reports of the Russian attack on September 3 primarily mention drones. Therefore, the confirmed wording at the moment is: the Teva warehouse was hit twice during a Russian air attack.
The final extent of the damage has also not yet been determined.
Particularly serious consequences of the attack were recorded in the Kyiv region.
In the Boryspil district, a man received shrapnel wounds and was hospitalized. Warehouse facilities, an administrative building, a store, and other civilian objects were damaged. In Boryspil itself, damage to two apartment buildings, cars, a bank building, and a beauty salon was also reported.
However, there is no reason to link the man’s injury directly to the Teva facility: there were no casualties among the company’s employees.
In the same Boryspil district, a strike hit a large pharmaceutical logistics complex “Biocon” — one of the largest specialized warehouse hubs in Ukraine, covering about 30,000 square meters.
“Biocon” is engaged in storing medicines and provides warehouse facilities to international pharmaceutical companies. According to participants in the Ukrainian pharmaceutical market, products from Pfizer, Novartis, Roche, Teva, AstraZeneca, and other manufacturers were stored there.
Significant stocks of medicines were reported destroyed. Preliminary damage to the entire complex was estimated by market representatives at billions of hryvnias, but the final amount of losses has not yet been determined.
At the same time, it is not possible to combine reports about “Biocon” and Teva into the same point without additional confirmations.
Teva separately officially reported two strikes on its warehouse. “Biocon” is separately mentioned as an affected large pharmaceutical logistics complex where, among other things, Teva products were stored. The available public data is insufficient to assert that all reports refer to the same specific warehouse facility.
During the same period, Russian attacks also affected humanitarian medical infrastructure.
One of the main warehouses of the World Health Organization in the Kyiv region, where humanitarian medical supplies were stored, was hit. WHO staff were not injured, but due to fire, smoke, and limited access, it was impossible to immediately determine the extent of the losses.
This is a continuation of a series of similar incidents. Previously, WHO warehouses in Dnipro and near Kyiv were damaged. In 2026, the organization reported at least 20 attacks on humanitarian aid warehouses, with 15 of them affecting medical supplies.
Thus, a broader context is visible around the Teva story: Russian attacks affect not only individual enterprises but also the infrastructure through which medicines and humanitarian medical aid are stored and distributed in Ukraine.
Teva condemned the Russian attacks
The company’s reaction was not limited to a statement about the damage.
Teva condemned the Russian attacks, stating on September 3, 2026, that they continue to take human lives, endanger people, and destroy civilian infrastructure and Ukrainian business.
The company separately emphasized that the pharmaceutical industry is part of the critically important healthcare system, so continuous access for patients to necessary treatment must be maintained even during war.
Teva’s General Manager in Ukraine, Dmitry Spitsyn, named two immediate priorities for the company: employee safety and maintaining patient access to medicines.
For many people, it is about medications that need to be taken constantly. Therefore, damage to such a facility means not only the loss of goods or commercial damage.
One of the elements of Ukraine’s medicine supply system is under attack.
Teva is indeed an Israeli company
This is important to clarify separately, as the structure of a large international corporation can create confusion.
The history of the company from which the modern Teva grew begins in Jerusalem in 1901. Chaim Salomon, Moshe Levin, and Yitzhak Elstein created a small wholesale pharmaceutical business S.L.E. — Salomon, Levin & Elstein, engaged in the import and distribution of medicines.
In the history of Teva itself, a characteristic detail of that era has been preserved: medicines were delivered around the region, including by mule and camel caravans.
Gradually, its own pharmaceutical production developed. In 1951, Teva’s shares began trading on the Tel Aviv Stock Exchange.
In 1976, the merger of several Israeli pharmaceutical manufacturers led to the formation of Teva Pharmaceutical Industries Ltd. The word Teva — טבע — in Hebrew means “nature”.
After that, international expansion began. Through a series of major acquisitions, the Israeli company turned into a global pharmaceutical group. Over the years, IVAX, Barr, Pliva, ratiopharm, Cephalon, and Actavis became part of its structure.
Today, Teva operates in dozens of markets, and its medicines are used daily by about 200 million people. At the same time, the company’s global headquarters is located in Israel.
Therefore, there is no need to call Teva simply “a company with Israeli roots.”
Teva Pharmaceutical Industries is an Israeli pharmaceutical corporation.
At the same time, it is a public company. Its shares are traded on stock exchanges and belong to many investors, so there is no single physical owner who owns all of Teva.
How “Teva Ukraine” is structured and who owns it
The Teva group has been operating in Ukraine since 1997.
The current LLC “Teva Ukraine”, EDRPOU code 34770471, was registered on December 11, 2006.
The company’s director is Dmitry Spitsyn. The main registered type of activity is wholesale trade in pharmaceutical goods.
The legal ownership structure is as follows: 100% of the authorized capital of LLC “Teva Ukraine” belongs to Teva Pharma B.V., registered in the Netherlands. The registered capital of the Ukrainian enterprise is about 1.756 billion hryvnias.
But Teva Pharma B.V. is a structure of the international Teva group. “Teva Ukraine” itself directly states that it is part of Teva Pharmaceutical Industries Ltd. with headquarters in Israel.
Therefore, the definition “Ukrainian subsidiary of Israeli Teva” is correct.
It is not about an independent Ukrainian enterprise that was once allowed to use the Israeli brand. The direct legal owner of the Ukrainian LLC is the Dutch structure of the group, and above it is the global Israeli Teva Pharmaceutical Industries.
In Ukraine, this is far from a small representation.
Teva reports more than 350 employees and a portfolio of over 260 medicinal products. The company calls itself the largest international pharmaceutical company in Ukraine and one of the three industry leaders.
According to the financial statements for 2025, LLC “Teva Ukraine” received about 4.66 billion hryvnias in revenue, and its assets at the end of the year amounted to approximately 3.88 billion hryvnias.
More than $155 million in medicines and humanitarian aid to Ukraine
After the start of the full-scale Russian war, Teva did not leave Ukraine.
By October 2025, the company reported that it had provided the country with humanitarian aid worth more than $155 million.
This is more than 3.2 million packages of essential medicines and over 400 types of drugs.
The humanitarian supplies included medicines for patients with cardiovascular diseases, diabetes and other endocrine disorders, neurological and mental illnesses, infections, gastrointestinal diseases, as well as oncological and hematological diseases.
The aid was delivered through Teva’s Ukrainian division, the company’s global structures, and in partnership with Direct Relief. Recipients included the Ukrainian healthcare system, charitable foundations, and humanitarian organizations.
Therefore, the situation looks particularly indicative.
An Israeli company has been operating in Ukraine for almost three decades, after the Russian invasion, it provides the country with medicines and humanitarian aid worth more than $155 million — and now its own warehouse is hit twice by Russian strikes.
And in the same days, Moscow sets conditions for Israel
At this point, the story ceases to be just a Ukrainian episode.
Almost simultaneously, it became known that Russian aviation authorities did not give El Al the necessary positive decision to open the Tel Aviv — St. Petersburg route.
As already thoroughly analyzed by NANews — News of Israel in the material about the conflict around El Al and Aeroflot, Israeli sources link Moscow’s position with the issue of returning the Russian carrier to Ben Gurion.
Here, too, it is important to separate the established fact and the reports of sources.
Fact: El Al did not receive the necessary Russian permission.
According to Israeli sources: Moscow is not interested in expanding El Al’s opportunities until Aeroflot itself can return to Israel.
At the same time, there was no official Russian statement in direct form — “we will not give El Al St. Petersburg until Israel allows Aeroflot” — published.
And all this happens just two days after the publication of the Financial Times investigation into the Russian-Iranian C430L program. NANews separately analyzed the assistance of Russian missile specialists to Iran.
According to FT, Russian specialists helped Tehran master supersonic cruise missile technologies, and cooperation continued in 2026.
The picture ultimately becomes significantly broader than the story of one warehouse.
Russia is waging war against Ukraine. Israeli Teva helps the Ukrainian healthcare system — and its warehouse is hit twice by Russian strikes.
Simultaneously, Russian specialists help Iran develop missile technologies.
And in the aviation dispute with Israel, Moscow, according to Israeli sources, uses the issue of permission for El Al as leverage around Aeroflot’s interests.
On August 31, Ukrainian Ambassador Yevhen Korniychuk in Tel Aviv spoke about the need to unite the efforts of Ukraine and Israel against common threats. We then separately analyzed why the connection between Russia and Iran is becoming more noticeable behind this wording.
Now, to diplomatic statements, two strikes on the warehouse of one of the largest Israeli companies have been added.
At the time of preparing the material, a separate public reaction from the Israeli government specifically to what happened with the Teva warehouse could not be found.
Teva itself has already formulated its position: the company condemned the Russian attacks.
And after this story, the question to the current Israeli government becomes even more specific: how many such episodes need to accumulate for relations with Moscow to be assessed not out of habit and diplomatic inertia, but based on what Russia is actually doing with Israeli interests today — from big business and aviation to cooperation with Iran?